港股異動 | 復星醫藥AH股齊漲 子公司新藥獲批開展臨牀試驗
格隆匯10月14日丨復星醫藥(2196.HK)現報36.05港元,漲3.74%,暫成交2.9億港元,最新H股市值923億港元;復星醫藥(600196.SH)現報61.28元,漲4.13%,暫成交51億元,最新A股市值1570億元。復星醫藥昨日盤後發公告稱,控股子公司復星醫藥產業收到國家藥品監督管理局關於同意其獲許可的馬來酸阿伐曲泊帕片開展臨牀試驗的通知書。該藥品用於成人慢性免疫性血小板減少症適應症(ITP),復星醫藥產業擬於近期條件具備後於中國境內開展該新藥針對該適應症的III期臨牀試驗。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.